Amir Heshmatpour Buys 12,000 Shares of Neonc Technologies (NASDAQ:NTHI) Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour bought 12,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average cost of $3.79 per share, for a total transaction of $45,480.00. Following the transaction, the chief executive officer owned 3,084,000 shares of the company’s stock, valued at $11,688,360. The trade was a 0.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Neonc Technologies Price Performance

NTHI opened at $5.53 on Wednesday. Neonc Technologies Holdings, Inc. has a fifty-two week low of $3.01 and a fifty-two week high of $12.99. The company’s 50-day moving average is $4.14 and its 200 day moving average is $6.02.

Neonc Technologies (NASDAQ:NTHI) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

More Neonc Technologies News

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: NEO100 reached a Phase 2a endpoint: The company reported that NEO100 produced positive Phase 2a results in recurrent IDH1-mutant high-grade glioma, including extended survival. The update strengthens the investment case for NeOnc’s central-nervous-system drug platform and could support further development or partnership interest. Neonc NEO100 Hits Phase II Endpoint, Extends Survival in Recurrent Glioma
• Positive Sentiment: Repeated CEO insider buying is supporting sentiment: Heshmatpour purchased 12,000 shares on August 14 for approximately $45,480, 3,000 shares on August 17 for $13,110, and another 9,000 shares on August 18 for $49,860. The purchases increased his already substantial ownership and signal management confidence, although insider buying does not guarantee clinical or financial success. SEC Form 4 Filing
• Neutral Sentiment: Analyst views remain mixed: Several firms maintain Buy ratings and price targets ranging from $13 to $20, while other services have issued Hold or Sell opinions. The reported consensus rating is Hold, highlighting both the substantial upside analysts see and the risks surrounding this early-stage biotech.
• Neutral Sentiment: Shareholder actions expand financing capacity: Stockholders elected directors and approved an expansion of the equity plan by 1 million shares. The authorization may provide capital for development, but it also creates potential future dilution for existing shareholders. NeOnc Stockholders Elect Directors, Approve Equity Plan Expansion
• Negative Sentiment: Recent earnings results were weak: NeOnc reported a quarterly loss of $0.58 per share, significantly wider than the $0.12 loss analysts expected. The miss underscores the company’s ongoing cash-burn and execution risks while its clinical programs remain in development.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NTHI. BTIG Research reaffirmed a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, May 26th. Alliance Global Partners assumed coverage on Neonc Technologies in a research report on Tuesday, May 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Weiss Ratings lowered Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, June 24th. Maxim Group started coverage on Neonc Technologies in a research note on Monday, May 18th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Neonc Technologies presently has an average rating of “Hold” and an average price target of $16.00.

Institutional Investors Weigh In On Neonc Technologies

A number of hedge funds have recently modified their holdings of the stock. Barclays PLC grew its holdings in Neonc Technologies by 5,314.8% during the fourth quarter. Barclays PLC now owns 9,151 shares of the company’s stock valued at $76,000 after purchasing an additional 8,982 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Neonc Technologies in the fourth quarter valued at $124,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Neonc Technologies during the 4th quarter valued at $126,000. Global Retirement Partners LLC purchased a new position in shares of Neonc Technologies during the 2nd quarter valued at $126,000. Finally, Royal Bank of Canada bought a new position in shares of Neonc Technologies during the 1st quarter worth $247,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.